BIOMARKER-GUIDED DRUG DEVELOPMENT FOR PERSONALIZED MEDICINE
Keywords:
biomarker; personalized medicine; precision medicine; predictive biomarker; companion diagnostic; drug development; clinical validation; adaptive enrichment.Abstract
Biomarker-guided drug development is a central operational strategy for personalized medicine because it links biological heterogeneity with decisions on target population, dose, safety, efficacy, and treatment selection. The objective of this article is to synthesize the methodological, analytical, clinical, and regulatory principles required to translate biomarkers from discovery into decision-grade tools in drug development. A structured narrative review of peer-reviewed international literature and authoritative FDA–NIH resources was conducted, with emphasis on biomarker definitions, fit-for-purpose assay validation, predictive biomarker trial designs, adaptive enrichment, companion diagnostics, and emerging liquid-biopsy approaches. The evidence synthesis shows that biomarker value is determined not by novelty alone but by a clearly defined context of use, analytical performance, biological plausibility, clinical validation, and demonstration that the biomarker changes a development or treatment decision. Predictive biomarkers are particularly important for personalized medicine because they identify patients with differential likelihood of benefit or harm from a specific intervention, whereas prognostic biomarkers characterize outcome independent of treatment. Biomarker-enriched and biomarker-by-treatment interaction designs can increase trial efficiency when the underlying hypothesis is strong, while adaptive designs can preserve broader learning when uncertainty remains. Companion diagnostic co-development requires early alignment among assay developers, clinical teams, statisticians, and regulators. The major barriers are pre-analytical variability, assay drift, cut-point instability, tumor and disease heterogeneity, multiplicity, insufficient external validation, and inequitable access to testing. A fit-for-purpose, iterative framework that integrates molecular biology, robust bioanalytics, prospective statistical planning, and regulatory context can improve the probability that biomarker programs deliver clinically meaningful personalized therapies.
References
1.FDA–NIH Biomarker Working Group. (2016–2025). BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD: U.S. Food and Drug Administration; Bethesda, MD: National Institutes of Health. NCBI Bookshelf.
2.Califf, R. M. (2018). Biomarker definitions and their applications. Experimental Biology and Medicine, 243(3), 213–221. https://doi.org/10.1177/1535370217750088
3.Kraus, V. B. (2018). Biomarkers as drug development tools: discovery, validation, qualification and use. Nature Reviews Rheumatology, 14(6), 354–362. https://doi.org/10.1038/s41584-018-0005-9
4.Schuck, R. N., & Sekar, V. (2025). Use of biomarkers in drug development for regulatory purposes. Clinical and Translational Science, 18(10), e70377. https://doi.org/10.1111/cts.70377
5.Chau, C. H., Rixe, O., McLeod, H., & Figg, W. D. (2008). Validation of analytic methods for biomarkers used in drug development. Clinical Cancer Research, 14(19), 5967–5976. https://doi.org/10.1158/1078-0432.CCR-07-4535
6.Cummings, J., Raynaud, F., Jones, L., Sugar, R., & Dive, C. (2010). Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. British Journal of Cancer, 103(9), 1313–1317. https://doi.org/10.1038/sj.bjc.6605910
7.Lee, J. W., & Hall, M. (2009). Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. Journal of Chromatography B, 877(13), 1259–1271. https://doi.org/10.1016/j.jchromb.2008.11.022
8.Zineh, I., & Huang, S. M. (2011). Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomarkers in Medicine, 5(6), 705–713. https://doi.org/10.2217/bmm.11.90
9.Mandrekar, S. J., & Sargent, D. J. (2009). Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology, 27(24), 4027–4034. https://doi.org/10.1200/JCO.2009.22.3701
10.Simon, R. (2014). Biomarker based clinical trial design. Chinese Clinical Oncology, 3(3), 39. https://doi.org/10.3978/j.issn.2304-3865.2014.02.03
11.Simon, N., & Simon, R. (2013). Adaptive enrichment designs for clinical trials. Biostatistics, 14(4), 613–625. https://doi.org/10.1093/biostatistics/kxt010
12.Jørgensen, J. T. (2021). The current landscape of the FDA approved companion diagnostics. Translational Oncology, 14(6), 101063. https://doi.org/10.1016/j.tranon.2021.101063
13.Serelli-Lee, V., Ito, K., Koibuchi, A., Tanigawa, T., Ueno, T., Matsushima, N., & Imai, Y. (2022). A state-of-the-art roadmap for biomarker-driven drug development in the era of personalized therapies. Journal of Personalized Medicine, 12(5), 669. https://doi.org/10.3390/jpm12050669
14.Thompson, M. K., Gale, D., & Brenton, J. D. (2021). Circulating tumour DNA for clinicians: current and future clinical applications. Clinical Radiology, 76(10), 737–747. https://doi.org/10.1016/j.crad.2021.07.005
15.Kadam, H., Vora, A., & Sharma, S. (2026). Companion diagnostic: An overview of regulatory framework, challenges, and future directions. Annales Pharmaceutiques Françaises, 84(2), 149–160. https://doi.org/10.1016/j.pharma.2025.11.010
